snowballjeffrey

Learning biotech, quant finance & programming.

[snowballjeffrey @che38917]

@thee1LOE @CNote_100RR @grok true?

[snowballjeffrey @che38917]

@BiotechAutist You good?

[snowballjeffrey @che38917]

@jy201506 "Based on FDA’s own published analysis"

[snowballjeffrey @che38917]

@kainvests The question of Iovance is more on the commercial side. Cell therapy is tough business.

[snowballjeffrey @che38917]

@BiotechAutist Im long at 2.2 diluted cost. Added some more the day before Adcom. FDA made a lot of mistakes on this one. The review team is too junior to interpret the data.

[snowballjeffrey @che38917]

@RxRegA Why changing the format? So fda have more time to cover their technical weaknesses? Why the review teams can’t do a better job? I have a proposal for the fda: make the Adcom mandatory for the sake of transparency

[snowballjeffrey @che38917]

@BiotechAutist Gambling

[snowballjeffrey @che38917]

@Andre_AGTC The data aren't messy at all.

[snowballjeffrey @che38917]

@jy201506 Base case is approval. CRL was given because the review team failed its job

[snowballjeffrey @che38917]

@BIOTECHSCANNER I love your confidence. It reminds me of Vinay Prasad

[snowballjeffrey @che38917]

@BiotechAutist you good?

[snowballjeffrey @che38917]

@BiotechAutist ?

[snowballjeffrey @che38917]

@AppleHelix Prasad cult

[snowballjeffrey @che38917]

@adamfeuerstein You're the best biotech journalist without a biotech background.

[snowballjeffrey @che38917]

@adamfeuerstein Brutal for the FDA or $REPL?

[snowballjeffrey @che38917]

@AppleHelix Yes.

[snowballjeffrey @che38917]

@biotech_hunter I miss the Peter Marks days.

[snowballjeffrey @che38917]

@BiotechAutist @biotech_hunter This proves how wrong he was

[snowballjeffrey @che38917]

@adamfeuerstein Obviously. You didn't know because you have no science background